Stockscreener 앱 받기
3.855
1.37%
0.055
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech to Release Fourth Quarter and Full Year 2025 Financial Results - geneonline.com
Alvotech to Announce Q4 and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results - ChartMill
Alvotech (ALVO) Stock Analysis: Exploring A Potential 375% Upside In The Biosimilar Market - DirectorsTalk Interviews
Alvotech : Managers' transactionsALVOTECH - marketscreener.com
Alvotech’s Biosimilar Bet: Why Wall Street Is Suddenly Watching - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at 3.89 USD - Investing.com
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Alvotech Discloses Intra-Group Transfer of 2.7 Million Shares Within Aztiq Group - TipRanks
Alvotech (NASDAQ: ALVO) discloses 2.7M-share intra-group transfer at $4.74 - Stock Titan
2.7 million Alvotech shares change hands inside owner group - Stock Titan
Alvotech (ALVO) Is Down 9.1% After FDA Rejects AVT05 Over Facility Issues and Legal Probe - simplywall.st
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech - GlobeNewswire
Alvotech begins European rollout of first-ever Simponi biosimilar Gobivaz - MSN
Alvotech (NASDAQ:ALVO) Cut to Strong Sell at Zacks Research - Defense World
Alvotech (NASDAQ:ALVO) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Alvotech stock hits 52-week low at $4.31 amid challenging year - Investing.com Australia
Alvotech (NASDAQ:ALVO) Reaches New 1-Year LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Trading Down 5.7%Here's Why - MarketBeat
Alvotech (ALVO): A 378% Upside Potential In The Biosimilar Market - DirectorsTalk Interviews
Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide? - simplywall.st
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump - Yahoo Finance
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook - Yahoo Finance
How Alvotech Equity Warrant stock performs during Fed tightening cyclesEarnings Overview Summary & Free Safe Capital Growth Stock Tips - mfd.ru
Can Alvotech Equity Warrant maintain its current growth rateQuarterly Trade Summary & Accurate Entry and Exit Point Alerts - mfd.ru
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 - Finviz
Can Alvotech be recession proofJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
12 Best Penny Stocks That Will Skyrocket - Insider Monkey
Is Alvotech the Next Big Biotech Rocket or Just Hype? Real Talk on This Viral Underdog Stock - AD HOC NEWS
How Alvotech (ALVO) Affects Rotational Strategy Timing - Stock Traders Daily
Alvotech’s AVT03 Biosimilar Gains European Approval - MSN
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Alvotech Announces Increase in Number of Own Shares - ChartMill
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech - GlobeNewswire
Press releases provided by CNW - Techaeris
Aug Drivers: What is the Moat Score of Alvotech Equity WarrantQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Alvotech Faces Securities Claims Investigation - Intellectia AI
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - morningstar.com
Alvotech Enters Supply and Commercialization Agreements for Canada and Australia & New Zealand Covering Multiple Biosimilar Candidates - 富途牛牛
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)? - simplywall.st
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio - MSN
Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings - Citeline News & Insights
Private Equity Firms Are Alvotech's (NASDAQ:ALVO) Biggest Owners and Were Hit After Market Cap Dropped US$63m - 富途牛牛
Alvotech Hits Pivotal Milestone With Positive PK Data for Entyvio Biosimilar AVT80 - TipRanks
Alvotech (NASDAQ: ALVO) posts positive pivotal data for Entyvio biosimilar - Stock Titan
Alvotech Reports Positive Top-line Pharmacokinetic Study Results For AVT80, A Biosimilar To Entyvio - Nasdaq
Why Is ALVO Stock Rising Pre-Market Today? - Stocktwits
0.25%
0.50%
자본화:
|
볼륨(24시간):